Compare FLL & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLL | NTHI |
|---|---|---|
| Founded | 1987 | 2008 |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.3M | 114.6M |
| IPO Year | 2014 | N/A |
| Metric | FLL | NTHI |
|---|---|---|
| Price | $2.65 | $4.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $4.00 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 183.8K | 94.9K |
| Earning Date | 05-07-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.45 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $302,376,000.00 | N/A |
| Revenue This Year | $7.54 | N/A |
| Revenue Next Year | $6.49 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.53 | N/A |
| 52 Week Low | $2.02 | $3.71 |
| 52 Week High | $4.95 | $12.99 |
| Indicator | FLL | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 46.54 | 45.30 |
| Support Level | $2.57 | $4.49 |
| Resistance Level | $2.74 | $5.78 |
| Average True Range (ATR) | 0.13 | 0.28 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 18.75 | 26.46 |
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins. Geographically, it operates in United States.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.